BR112021021481A2 - Conjugados de citocina de liberação lenta - Google Patents
Conjugados de citocina de liberação lentaInfo
- Publication number
- BR112021021481A2 BR112021021481A2 BR112021021481A BR112021021481A BR112021021481A2 BR 112021021481 A2 BR112021021481 A2 BR 112021021481A2 BR 112021021481 A BR112021021481 A BR 112021021481A BR 112021021481 A BR112021021481 A BR 112021021481A BR 112021021481 A2 BR112021021481 A2 BR 112021021481A2
- Authority
- BR
- Brazil
- Prior art keywords
- slow
- cytokine conjugates
- release cytokine
- release
- conjugates
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 3
- 108090000695 Cytokines Proteins 0.000 title abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839112P | 2019-04-26 | 2019-04-26 | |
| PCT/US2020/029911 WO2020219943A1 (en) | 2019-04-26 | 2020-04-24 | Slow-release cytokine conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021481A2 true BR112021021481A2 (pt) | 2021-12-21 |
Family
ID=72941771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021481A BR112021021481A2 (pt) | 2019-04-26 | 2020-04-24 | Conjugados de citocina de liberação lenta |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220193253A1 (https=) |
| EP (1) | EP3958888A4 (https=) |
| JP (2) | JP7608360B2 (https=) |
| KR (1) | KR20220004134A (https=) |
| CN (1) | CN114126638A (https=) |
| AU (1) | AU2020261076B2 (https=) |
| BR (1) | BR112021021481A2 (https=) |
| CA (1) | CA3136726A1 (https=) |
| MX (1) | MX2021012813A (https=) |
| SG (1) | SG11202111175YA (https=) |
| WO (1) | WO2020219943A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019028419A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
| ES3059360T3 (en) | 2018-11-08 | 2026-03-19 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| KR20260039812A (ko) | 2019-02-06 | 2026-03-20 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
| CN114555632A (zh) | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| MX2022002740A (es) | 2019-09-10 | 2022-03-25 | Synthorx Inc | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. |
| CA3153644A1 (en) * | 2019-09-30 | 2021-04-08 | Beijing Xuanyi Pharmasciences Co., Ltd. | Protein-macromolecule conjugates and methods of use thereof |
| WO2022115563A1 (en) * | 2020-11-25 | 2022-06-02 | Prolynx Llc | Extended release hydrogel conjugates of c-natriuretic peptides |
| AU2022249281B2 (en) * | 2021-03-29 | 2025-08-14 | Aj Sciences (Yixing) Co., Ltd | Protein-macromolecule conjugates and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7052686B2 (en) * | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
| MXPA06014465A (es) * | 2004-06-10 | 2007-05-16 | Zymogenetics Inc | Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion. |
| EP2566335B1 (en) * | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| US8703907B2 (en) * | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| KR102109067B1 (ko) * | 2011-09-07 | 2020-05-13 | 프로린크스 엘엘시 | 생분해성 교차결합을 가지는 하이드로젤 |
| DK2986312T3 (da) | 2013-04-19 | 2022-02-14 | Cytune Pharma | Cytokinafledt behandling med reduceret vaskulært lækagesyndrom |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| WO2016025385A1 (en) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| US20180360977A1 (en) * | 2015-12-21 | 2018-12-20 | Armo Biosciences, Inc. | Interleukin-15 Compositions and Uses Thereof |
| WO2019028419A1 (en) * | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
-
2020
- 2020-04-24 KR KR1020217038681A patent/KR20220004134A/ko active Pending
- 2020-04-24 US US17/606,687 patent/US20220193253A1/en active Pending
- 2020-04-24 CN CN202080046706.5A patent/CN114126638A/zh active Pending
- 2020-04-24 AU AU2020261076A patent/AU2020261076B2/en active Active
- 2020-04-24 EP EP20795140.1A patent/EP3958888A4/en active Pending
- 2020-04-24 JP JP2021563306A patent/JP7608360B2/ja active Active
- 2020-04-24 CA CA3136726A patent/CA3136726A1/en active Pending
- 2020-04-24 SG SG11202111175YA patent/SG11202111175YA/en unknown
- 2020-04-24 BR BR112021021481A patent/BR112021021481A2/pt unknown
- 2020-04-24 WO PCT/US2020/029911 patent/WO2020219943A1/en not_active Ceased
- 2020-04-24 MX MX2021012813A patent/MX2021012813A/es unknown
-
2024
- 2024-12-18 JP JP2024221659A patent/JP2025063045A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114126638A (zh) | 2022-03-01 |
| US20220193253A1 (en) | 2022-06-23 |
| JP2022530462A (ja) | 2022-06-29 |
| EP3958888A1 (en) | 2022-03-02 |
| KR20220004134A (ko) | 2022-01-11 |
| WO2020219943A1 (en) | 2020-10-29 |
| CA3136726A1 (en) | 2020-10-29 |
| AU2020261076A1 (en) | 2021-11-18 |
| SG11202111175YA (en) | 2021-11-29 |
| AU2020261076B2 (en) | 2026-01-22 |
| MX2021012813A (es) | 2022-03-17 |
| JP2025063045A (ja) | 2025-04-15 |
| JP7608360B2 (ja) | 2025-01-06 |
| EP3958888A4 (en) | 2023-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021021481A2 (pt) | Conjugados de citocina de liberação lenta | |
| BR112022012112A2 (pt) | Agonistas de il2 e métodos de uso dos mesmos | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| WO2019173832A3 (en) | Cytokine prodrugs | |
| BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
| ECSP22012826A (es) | Inhibidores de parp1 | |
| MX2020013169A (es) | Conjugados de camptotecina. | |
| CO2020012505A2 (es) | Picolinamidas como fungicidas | |
| AR112969A1 (es) | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas | |
| IL285254A (en) | Compositions containing, methods and uses of antibody-tlr agonist conjugates | |
| MX2020001270A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. | |
| MX2021016050A (es) | Formulaciones transdermicas. | |
| MX2020009330A (es) | Pares de citocinas/receptores ortogonales biologicamente relevantes. | |
| MX2021007845A (es) | Anticuerpos contra il-4ra humano y uso de los mismos. | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| ECSP21068097A (es) | Anticuerpos claudina 6 y usos de los mismos | |
| UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
| DK3962601T3 (da) | 5-HT2A-agonister til anvendelse til behandling af depression | |
| DOP2021000170A (es) | Formulacion de anticuerpos terapeuticos | |
| IL291730A (en) | Protein-macromolecule conjugates and methods of use thereof | |
| BR112022010143A2 (pt) | Inibidores de ahr e usos respectivos | |
| EP4171609A4 (en) | CYTOKINE CONJUGATES | |
| EP4143323A4 (en) | CYTOKINE IMMUNOTHERAPY | |
| MA56543A (fr) | Formulations de pénétration transdermique |